NKTR

Nektar Announces UCB's Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis

...ed in Cimzia(R) Through Exclusive Nektar-UCB Collaboration SAN FRANCISCO, Calif., May 14 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) confirmed today UCB's announcement that the US Food and Drug Administration (FDA) has approved Cimzia(R) (certolizumab pegol), the only PEGylated an...

Nektar Therapeutics to Present at the Deutsche Bank 34th Annual Health Care Conference in Boston

... SAN CARLOS, Calif., May 12 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) is scheduled to present at the upcoming Deutsche Bank 34th Annual Health Care Conference in Boston at the Boston InterContinental Hotel on Monday, M...

Nektar to Announce Financial Results for the First Quarter of 2009 on Wednesday, May 6, 2009, After Close of U.S.-Based Financial Markets

... SAN CARLOS, Calif., April 29 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) will announce its financial results for the first quarter ended March 31, 2009 on Wednesday, May 6, 2009, after the close of U.S.-based financial ma...

NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR

... DENVER and SAN CARLOS, Calif., April 22 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) presented data today at the American Association for Cancer Research (AACR) 100th Annual Meeting demonstrating that NKTR-105, a novel PEGylated form...

Dosing Begins in Phase 1 Clinical Study Evaluating NKTR-105 in Cancer Patients With Refractory Solid Tumors

... SAN CARLOS, Calif., Feb. 17 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) announced today that the first patients have been dosed in a Phase 1 dose-escalation study of NKTR-105, a novel PEGylated form of docetaxel. The Ph...

Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results

... SAN CARLOS, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) today announced that it has repurchased 32%, or $100.0 million, of its outstanding convertible debt for approximately 48 cents on the dollar, for a ...

Nektar to Announce Financial Results for the Third Quarter of 2008 on Thursday, November 6, 2008 After Close of U.S.-Based Financial Markets

... SAN CARLOS, Calif., Oct 23 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) will announce its financial results for the third quarter ended September 30, 2008 on Thursday, November 6, 2008, after the close of U.S.-based fina...

Nektar Therapeutics Announces Second Quarter 2008 Results

... SAN CARLOS, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) today announced the company's financial results for the second quarter and six-months ended June 30, 2008. Cash, cash equivalents, and short-term ...

Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer

... SAN CARLOS, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) today announced the appointment of Randall Moreadith, M.D., Ph.D., to the position of Senior Vice President of Drug Development and Chief Developmen...

Nektar Therapeutics Announces First Quarter 2008 Results

... SAN CARLOS, Calif., May 7 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) announced today the company's financial results for the first quarter ended March 31, 2008. Cash, cash equivalents, and short-term investments wer...

NKTR in Medical Technology

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

... SAN CARLOS, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) today reported its financial results for the second quarter ended June 30, 2009. Net loss for the quarter ended June 30, 2009 was $32.1 mill...

Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)

...s Achieved at Two Dose Levels with No Reversal of Analgesia SAN CARLOS, Calif., March 2 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) announced positive topline results today from a Phase 2 double-blind, randomized, placebo-controlled study of NKTR-118 in patients with opioid-induc...

Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)

...in Advanced Breast and Ovarian Cancers SAN CARLOS, Calif., June 2 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) today announced an expanded Phase 2 development plan for NKTR-102 (PEG-irinotecan). The company will target newly-characterized colorectal cancer pa...

Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)

... SAN CARLOS, Calif., May 30 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) will host a meeting and Webcast on Monday, June 2, 2008 at 6:30 PM Central Time to discuss the company's lead oncology program, NKTR-102 (PEG-irinot...

Amikacin Inhale Shows Promising Results in Phase II Study

... mechanically-ventilated patients TORONTO and BERLIN, May 19 /PRNewswire-FirstCall/ -- Bayer HealthCare together with Nektar Therapeutics (Nasdaq: nktr ), today presented positive preliminary Phase II data on their unique drug-device combination Amikacin Inhale at the American Thoracic Society (ATS) a...

Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings

...Molecule with Demonstrated Therapeutic Activity SAN CARLOS, Calif., May 16 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) announced initial results today from a Phase 1 study of NKTR- 102, PEGylated irinotecan. The data shows significant anti-tumor activity in patients ...

NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting

...f., May 7 /PRNewswire-FirstCall/ -- New Phase 1 clinical trial results for NKTR-118 (oral PEG-naloxol) were presented by Nektar Therapeutics (Nasdaq: nktr ) this week at the Annual Meeting of the American Pain Society (APS) in Tampa, Florida. In this multiple-dose Phase 1 study, oral NKTR-118 was shown t...

Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting

... SAN FRANCISCO, April 14 /PRNewswire-FirstCall/ -- Positive preclinical data was presented by Nektar Therapeutics (Nasdaq: nktr ) this week for its lead oncolytic candidate, NKTR-102 (PEG-irinotecan), which demonstrated enhanced anti-tumor activity in a mouse xenograft model of...

Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings

... SAN FRANCISCO, April 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) announced today that positive preclinical and clinical results for its pipeline programs will be presented at numerous medical and scientific meetin...

Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients

... SAN CARLOS, Calif., April 9, 2008 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) announced today that it has ceased all negotiations with potential partners for its inhaled insulin programs as a result of new data analysis from o...

NKTR in Biological Technology

Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City

... SAN CARLOS, Calif., July 31 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) is scheduled to present at the upcoming BMO Capital Markets 9th Annual Focus on Healthcare Conference at the Millennium Broadway Hotel in New York...

Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets

... SAN CARLOS, Calif., July 31 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) will announce its financial results for the second quarter ended June 30, 2009 on Tuesday, August 4, 2009, after the close of U.S.-based financial m...

Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer

... SAN CARLOS, Calif., June 9 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) today announced the promotion of Lorianne Masuoka, M.D. to the position of Chief Medical Officer. Dr. Masuoka reports to Nektar's Senior Vice Presi...

Nektar Therapeutics Reports First Quarter 2009 Financial Results

... SAN CARLOS, Calif., May 6 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) today reported its financial results for the first quarter ended March 31, 2009. Net loss for the quarter ended March 31, 2009 was $31.8 milli...

Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston

... SAN CARLOS, Calif., March 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics' (Nasdaq: nktr ) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming Cowen and Company 29th Annual Healthcare Conference ...

Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results

... SAN CARLOS, Calif., Feb. 24 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) today reported its financial results for the fourth quarter and year ended December 31, 2008. "2008 was a transformational year for Nektar," ...

Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets

... SAN CARLOS, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) will announce its financial results for the fourth quarter and year ended December 31, 2008 on Wednesday, February 25, 2009, after the close of U.S....

Nektar Announces Retirement of Irwin Lerner from Board of Directors

... SAN CARLOS, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) announced today that Irwin Lerner has retired from its Board of Directors effective January 23, 2009. Mr. Lerner, former Chairman of Hoffmann-La Ro...

First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer

... SAN CARLOS, Calif., Jan. 13 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) announced today that dosing has started in a Phase 2 clinical trial of NKTR-102 in platinum-resistant ovarian cancer. Regulatory approvals have als...

Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco

... SAN CARLOS, Calif., Jan. 5 /PRNewswire-FirstCall/ -- Nektar Therapeutics' (Nasdaq: nktr ) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 27th Annual J.P. Morgan Healthcare Conference in San...